Enrique Grande, Medical Oncology Department Director at Quironsalud Madrid, Adjunct Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:
“The FDA has approved adjuvant belzutifan + pembrolizumab for clear cell RCC at intermediate-high risk of recurrence after nephrectomy.
LITESPARK-022 data: HR 0.72 (95% CI 0.59–0.87; p=0.0003) in DFS vs pembrolizumab alone. Median DFS not reached in either arm.
A meaningful step forward in a setting where we needed better options.”
Other articles about Renal Cell Carcinoma on OncoDaily.